2018 Distinguished Faculty

Adam J. Adler, PhD, Professor, Immunology, University of Connecticut
Prasad S. Adusumilli, MD, FACS, FCCP, Associate Attending and Deputy Chief, Thoracic Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan Kettering Cancer Center
Gheath Alatrash, MD, PhD, Associate Professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Andrew Allen, PhD, CEO & President, Gritstone Oncology
Robert Allen, Senior Director, Oncolytic Virotherapy, Sorrento Therapeutics
David Anderson, PhD, CSO, Research & Development, VBI Vaccines, Inc.
Robert Anders, MD, PhD, Associate Professor, Pathology, Johns Hopkins University
Robert Ang, MD, CBO, Neon Therapeutics
Philip Arlen, MD, President & CEO, Precision Biologics
Justin Balko, PharmD, PhD, Assistant Professor, Medicine, Vanderbilt University Medical Center
Steven Banerjee, CEO, Mekonos, Inc.
Hila Barak, PhD, Senior Clinical Scientist, Cancer Immunotherapy, Genentech
John Bell, PhD, Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute
Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute
Phil Bland-Ward, PhD, CSO, Crescendo Biologics
Genevieve Boland, MD, PhD, Director, Melanoma Surgery Program, Massachusetts General Hospital; Director, Surgical Oncology Research Laboratories, Massachusetts General Hospital; Assistant Professor, Harvard Medical School; Associate Member, Broad Institute
Darrell R. Borger, PhD, Scientific Director, Immuno-Profiling Laboratory; Director, Translational Research/Biomarker Laboratory, Massachusetts General Hospital Cancer Center
Marcus W. Bosenberg, MD, PhD, Associate Professor, Dermatology and Pathology, Yale University
Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company
Benjamin Boyerinas, PhD, Senior Scientist, Immunotherapy, bluebird bio
Caroline Breitbach, PhD, Vice President, Translational Development, Turnstone Biologics
Joshua Brody, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai; Director, Lymphoma Immunotherapy Program
Tullia Bruno, PhD, Assistant Professor, Immunology, University of Pittsburgh and Hillman Cancer Center
Gabriella Campadelli, PhD, Co-Founder, Nouscom; Professor, Microbiology and Molecular Virology, University of Bologna
Alessandra Castiglioni, PhD, Senior Scientific Researcher, Cancer Immunology, Genentech
Saso Cemerski, PhD, Principal Scientist, Merck Research Labs
Kaan Certel, PhD, Head, Oncology External Innovation, Global Business Development & Licensing, Sanofi
Chien-Hsing Ken Chang, PhD, Vice President, Research and Development, Immunomedics
Pratip Chattopadhyay, PhD, Associate Professor, Pathology; Director, Precision Immunology Incubator, Isaac and Laura Perlmutter Cancer Center, New York University Langone Medical Center
Zhao Chen, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research
Nai-Kong Cheung, MD, PhD, Enid A. Haupt Endowed Chair in Pediatric Oncology, Memorial Sloan Kettering Cancer Center
Siu Tim Cheung, PhD, Associate Professor, Department of Surgery, The Chinese University of Hong Kong
Robert Coffin, PhD, Co-founder and CEO, Replimune
Ezra Cohen, MD, Professor, Medicine, University of California, San Diego
Matthew E. Colpoys, Jr., Co-Founder & CEO, Tactiva Therapeutics
Michael Comeau, Principal Scientist, Immunobiology, Aptevo Therapeutics
Jason Crawford, PhD, Associate Professor, Chemistry and Microbial Pathogenesis, Yale University
Razvan Cristescu, PhD, Senior Principal Scientist, Merck
Michael A. Curran, PhD, Assistant Professor, Immunology, The University of Texas MD Anderson Cancer Center
Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor
Agustin de la Calle, PhD, CBO, Eutilex Co., Ltd.
Liang Deng, MD, PhD, Lab Head, Dematologist, Memorial Sloan Kettering Cancer Center
Rakesh Dixit, DABT Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune
Janusz Dutkowski, PhD, CEO, Data4Cure, Inc.
Kenneth Emancipator, MD, Executive Medical Director and Head of Companion Diagnostics, Merck & Co.
Patrik Erlmann, PhD, Head, R&D, ViraTherapeutics
Maria Fardis, PhD, President & CEO, Iovance Biotherapeutics
Denise Faustman, MD, PhD, Associate Professor & Director, Immunobiology Lab, Massachusetts General Hospital, Harvard Medical School
Adam Foley-Comer, MD, CMO, KAHR Medical, Ltd.
Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Providence Health & Services, CEO, UbiVac
Agnete Fredriksen, PhD, President and CSO, Vaccibody AS
Philip Friedlander, MD, PhD, Assistant Professor, Medicine, Hematology & Medical Oncology; Director, Melanoma Medical Oncology Program, Icahn School of Medicine at Mount Sinai
Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
Christina Furebring, PhD, Senior Vice President, R&D, Alligator Bioscience
Richard Gaynor, MD, President, R&D, Neon Therapeutics
Christian Gieffers, PhD, Vice President, Analytics/Protein Chemistry, Apogenix
Michael Gladstone, Principal, Atlas Venture
Vancheswaran Gopalakrishnan, PhD, Post-doctoral Fellow, Laboratory of Dr. Jennifer Wargo, Surgical Oncology – Research, University of Texas MD Anderson Cancer Center
George A. Green, IV, PhD, Head, Pharmacodiagnostic Center of Excellence, Bristol-Myers Squibb
Steven A. Greenberg, MD, Professor, Neurology, Harvard Medical School; Brigham and Women’s Hospital; Abcuro, Inc.
Yuriy Gusev, PhD, Associate Professor, Innovation Center for Biomedical Informatics (ICBI), Georgetown University
John Gustofson, Managing Director, AbbVie Ventures
Bonnie Hammer, PhD, Vice President, Biologics Development, Invenra
Samir Hanash MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center
Brent Hanks, MD, PhD, Assistant Professor, Cancer Immunology/Immunotherapy, Duke Cancer Institute, Duke University School of Medicine
Elizabeth Hardaker, PhD, Head, Oncology In Vivo Pharmacology, AstraZeneca
William Hastings, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis
James Healy, General Partner, Sofinnova Ventures
Tina Hieken, MD, Associate Professor, Surgery, Mayo Clinic
Steven L. Highfill, PhD, Assistant Director, Product Development and Management, Center for Cellular Engineering, Clinical Center, National Institutes of Health
William Hildebrand, PhD, ABHI Diplomate, Chief Scientist, Pure MHC
Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies
Robert Iannone, MD, Senior Vice President & Head, Immuno-Oncology, Global Medicines Development, AstraZeneca
Robert Igarashi, PhD, President, CytoSen Therapeutics
Anika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH
Sarah Javaid, PhD, Associate Principal Scientist, Genetics and Pharmacogenomics, Merck
Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research
Douglas Jolly, PhD, EVP, R&D, Tocagen, Inc.
Teemu Junttila, PhD, Senior Scientist, Genentech
Pawel Kalinski, MD, PhD, Professor, Oncology, Vice-Chair, Translational Research, Roswell Park Cancer Institute
Shumei Kato, MD, Assistant Clinical Professor, Experimental Therapeutics, GI Medical Oncology & Rare Tumor Clinic, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center
Yisrael Katz, MD, Internal Medicine, ABIM, Arizona Biodesign Institute
Gunnar Kaufmann, PhD, SVP, Immunotherapy, Sorrento Therapeutics
W. Michael Kavanaugh, MD, CSO, Head, Research and Non-Clinical Development, Cytomx Therapeutics
Samir N. Khleif, MD, Director, The Loop Immuno-Oncology Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
David Kirn, MD, Co-Founder & Executive Chairman, IGNITE Immunotherapy
Matthias Klinger, PhD, Principal Scientist, BiTE Immunology, Amgen Research GmbH
Carsten Krieg, PhD, Assistant Professor of Immunology, Microbiology & Immunology and Dermatology, Medical University of South Carolina
Peiwen Kuo, PhD, Scientist, Nektar Therapeutics
Sean Lawler, PhD, Assistant Professor, Managing Director, Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital
Daniel Levey, PhD, Senior Director Vaccine Research, R&D, Agenus, Inc.
Doron Levy, PhD, Professor, Department of Mathematics, University of Maryland
Shulin Li, PhD, Professor, Director, Pediatric Laboratory Research Programs, W.T. and Louise Jarrett Moran Distinguished Chair, Pediatric Oncology, Pediatric Research, MD Anderson Cancer
Timothy K. Lu, MD, PhD, Associate Professor, Synthetic Biology Group, Research Laboratory of Electronics, Electrical Engineering and Computer Science, Biological Engineering, Massachusetts Institute of Technology
Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute
Jodi McKenzie, PhD, Senior Clinical Research Scientist, Investigational Cancer Therapeutics, MD Anderson Cancer Center
Matthew Meyer, PhD, Senior Investigator II, Oncology Pharmacology, Novartis Institutes for BioMedical Research, Inc.
Lance D. Miller, PhD, Mary Kirkpatrick Associate Professor of Breast Cancer Research, Wake Forest Baptist Comprehensive Cancer Center
Slavoljub Milosevic, PhD, Director, Technology Innovation, Medigene AG
Jaime F. Modiano, VMD, PhD, Perlman Professor of Oncology and Comparative Medicine, Veterinary Clinical Sciences, College of Veterinary Medicine and Masonic Cancer Center, University of Minnesota
Jürgen Moll, PhD, Director, Pharmacology and Translational Research, Boehringer Ingelheim
Charles Morris, PhD, CDO, Psioxus
Matthew Mulvey, PhD, CEO, BeneVir Biopharm, Inc.
Hiroshi Nakashima, PhD, Instructor, Neurosurgery, Brigham & Women's Hospital, Harvard Medical School
Flor C. Navarro, Research Scientist, Stephanie K. Watkins Laboratory, Biochemistry and Molecular Biology Loyola University Chicago
Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics
Shirley O'Dea, PhD, CSO, Avectas
Shuji Ogino, MD, PhD, Chief of Program in MPE Molecular Pathological Epidemiology, Brigham and Women’s Hospital (BWH); Professor (Pathology & Epidemiology), BWH, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health; Associate Member, Broad Institute of MIT and Harvard
Michael Olin, PhD, Assistant Professor, Pediatrics, University of Minnesota; CSO, OX2 Therapeutics
Shane Olwill, PhD, Vice President, Head of Development & Immuno-Oncology, Pieris Pharmaceuticals GmbH
Elena Orlando, PhD, Bioinformatics Investigator, Novartis Institutes for BioMedical Research
Michael Paglia, MSc, Vice President CMC Operations, Oncorus
Len Pagliaro, PhD, CEO, Siva Therapeutics, Inc.
Abhijit A. Patel, MD, PhD, Associate Professor, Therapeutic Radiology, Yale University School of Medicine
Marc Pelletier, MSc, Investigator III, Translational Immune Oncology, Novartis Institutes for Biomedical Research
Li Peng, PhD, Vice President, Biotherapeutics Discovery, Palleon Pharmaceuticals
Robert G. Petit, PhD, Executive Vice President & CSO, Advaxis
Kate Poropatich, MD, Instructor, Pathology and Radiation Oncology, Northwestern University Feinberg School of Medicine
George Poste, DVM, PhD, Chief Scientist, Complex Adaptive Systems, Arizona State University
Mark C. Poznansky, MD, PhD, Director, Vaccine & Immunotherapy Center, Massachusetts General Hospital; Associate Professor, Harvard Medical School
Richard Purcell, Executive Vice President, Research and Development, Generex Biotechnology
Christophe Queva, PhD, CSO, Oncorus
Samuel D. Rabkin, PhD, Professor, Neurosurgery, Massachusetts General Hospital and Harvard Medical School
Osama Rahma, MD, Assistant Professor of Medicine, Harvard Medical School; Center for Immuno-oncology, Dana-Farber Cancer Institute
Harun Rashid, PhD, Principal Scientist, Molecular Technology, Ambrx
Janet R. Rea, MSPH, RAC, Senior Vice President, Regulatory, Quality & Clinical Affairs, Atossa Genetics
Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.
Alexandre Reuben, PhD, Assistant Professor, MD Anderson Cancer Center
Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center
David L. Rimm, MD, PhD, Professor, Pathology, Yale University
Bruce Roberts, PhD, CSO, Vedanta Biosciences
Stephen J. Russell, MD, PhD, CEO, Vyriad, Inc.
Christoph Sachse, PhD, Site Head Berlin, NMI TT Pharmaservices
Niranjan Y. Sardesai, PhD, CEO & President, Geneos Therapeutics
Volker Schellenberger, PhD, President & CEO, Amunix
Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs
Dina Schneider, PhD, Manager, Cell Biology, Lentigen Technology, Inc.
Stephen Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology
Avi Schroeder, PhD, Assistant Professor, Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion – Israel Institute of Technology
Julianne Smith, PhD, Vice President, Translational Sciences, Cellectis
David M. Spencer, PhD, CTO, R&D, Bellicum Pharmaceuticals
Claudina Stevenson, PhD, Director, Search and Evaluation, Oncology, AbbVie
Zhen Su, MD, MBA, Senior Vice President & CMO, NA, EMD Serono, Inc.
Raymond Tesi, MD, President and CEO, Acting CMO, INmune Bio
Maude Tessier, Executive Director, Business Development, Boston Innovation Hub, Merck
Michael T. Tetzlaff, MD, PhD, Associate Professor, Pathology, The University of Texas MD Anderson Cancer Center
Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology, Johns Hopkins University
Mark Throsby, PhD, Executive Vice President & CSO, Merus NV
James B. Trager, PhD, Senior Vice President, R&D, Nkarta,Inc.
David Urech, PhD, Co-CEO and CSO, R&D, Numab Therapeutics AG
Bob Valamehr, PhD, MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics
Bruce Walcheck, PhD, Professor, Immunology, University of Minnesota
Even Walseng, PhD, Staff Scientist, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health; Department of Immunology, Hospital Radiumhospitalet, Institute for Cancer Research, University of Oslo
Allison Betof Warner, MD, PhD, Medical Oncology Fellow, Medicine, Memorial Sloan Kettering Cancer Center
William C. Watt, PhD, President & CEO, EpiThany
Kevin Webster, PhD, Senior Vice President, Cancer Biology, eFFECTOR Therapeutics
Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services
Glen J. Weiss, MD, MBA, Director, Phase 1 Clinical Research, Beth Israel Deaconess Medical Center, Boston
Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine
Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics
Glynn Wilson, PhD, Chairman and Strategic Advisor, TapImmune
Wilson Wong, PhD, Assistant Professor, Biomedical Engineering, Boston University
Jennifer Wu, PhD, Mary and Patrick Scanlan Professor of Urology, Northwestern University and Robert Lurie Comprehensive Cancer Center
Jun Xu, PhD, Associate Director, Product Development Laboratory, Center for Advanced Cellular Therapeutics, Perelman Center for Advanced Medicine, University of Pennsylvania
Wei Yan, PhD, CEO, Research, Sound Biologics
Niranjan Yanamandra, PhD, Scientific Director, Translational Research, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline
Masahide Yano, PhD, Research Scientist, CDER, FDA
Catharine Young, PhD, Senior Director, Science Policy, Biden Cancer Initiative
Hua Eleanor Yu, PhD, Professor & Co-Chair, Immuno-Oncology, City of Hope
Xingxing Zang, PhD, Louis Goldstein Swan Endowed Chair and Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine
Gus Zeiner, PhD, CSO, Chimera Bioengineering
Litao Zhang, PhD, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb
Lei Zheng, MD, PhD, Associate Professor, Oncology and Surgery, Johns Hopkins University School of Medicine
Ilan Zipkin, PhD, Vice President, Business Development, Parker Institute for Cancer Immunotherapy


Preliminary Agenda

Conference Programs